Pharma Mar (0RC6) Stock Overview
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0RC6 from our risk checks.
0RC6 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €100.80 |
| 52 Week High | €105.40 |
| 52 Week Low | €70.20 |
| Beta | 0.37 |
| 1 Month Change | 7.03% |
| 3 Month Change | 28.42% |
| 1 Year Change | 19.72% |
| 3 Year Change | 195.34% |
| 5 Year Change | 31.05% |
| Change since IPO | 112.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RC6 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.7% | 0.7% | 0.3% |
| 1Y | 19.7% | 27.1% | 18.8% |
Return vs Industry: 0RC6 underperformed the UK Biotechs industry which returned 27.1% over the past year.
Return vs Market: 0RC6 matched the UK Market which returned 18.8% over the past year.
Price Volatility
| 0RC6 volatility | |
|---|---|
| 0RC6 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0RC6 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RC6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 505 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma.
Pharma Mar, S.A. Fundamentals Summary
| 0RC6 fundamental statistics | |
|---|---|
| Market cap | €1.75b |
| Earnings (TTM) | €80.47m |
| Revenue (TTM) | €225.43m |
Is 0RC6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RC6 income statement (TTM) | |
|---|---|
| Revenue | €225.43m |
| Cost of Revenue | €12.52m |
| Gross Profit | €212.91m |
| Other Expenses | €132.45m |
| Earnings | €80.47m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.64 |
| Gross Margin | 94.45% |
| Net Profit Margin | 35.70% |
| Debt/Equity Ratio | 17.9% |
How did 0RC6 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 00:20 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Mar, S.A. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |